Orion Oyj stock (FI0009014377): Featured in global healthcare ETFs

Orion Oyj, a Finnish pharmaceutical company, is listed as a top holding in the VanEck Global Healthcare Leaders ETF (ASX: HLTH), representing 2.05% of the fund's net assets according to Ad-hoc-news.de as of recent data. This positioning underscores Orion Oyj's prominence in the global healthcare sector alongside peers like Otsuka Holdings and Hoya Corp. The ETF offers US investors access to large international healthcare names through a diversified portfolio.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Orion Oyj: core business model

Orion Oyj develops, manufactures and markets human pharmaceuticals and animal health products. The company focuses on proprietary medicines in areas such as neurological disorders, cancer and respiratory diseases. Its business model combines in-house R&D with partnerships for commercialization, serving markets primarily in Europe and beyond. Contract manufacturing also contributes to revenue stability.

Headquartered in Espoo, Finland, Orion Oyj operates through its own sales organizations in key Nordic and Baltic countries, while partnering with global players for wider distribution. This structure allows US investors exposure to European pharma innovation via ADRs or ETF holdings like VanEck's HLTH.

Main revenue and product drivers for Orion Oyj

Key products include Easyhaler inhalers for respiratory conditions and medicines like Odiparcil for thrombosis prevention. The company's proprietary portfolio generated the bulk of sales in recent periods, with contract manufacturing adding diversification. Orion Oyj's focus on specialty pharma positions it well in growing therapeutic areas relevant to US healthcare trends.

Revenue is driven by established brands and pipeline advancements, with Europe as the primary market. For US investors, Orion Oyj's ETF inclusion signals recognition in global healthcare portfolios tracking large-cap international names.

Industry trends and competitive position

The global healthcare sector benefits from aging populations and rising demand for innovative therapies, areas where Orion Oyj competes with firms like Otsuka Holdings. Its ETF feature in VanEck Global Healthcare Leaders reflects strong fundamentals among international peers. US investors value such exposure for diversification beyond domestic biotech.

Why Orion Oyj matters for US investors

Listed on Nasdaq Helsinki, Orion Oyj offers US investors indirect access through ETFs like HLTH, which includes US-traded healthcare names alongside globals. This provides balanced exposure to international pharma growth, complementing S&P 500 healthcare holdings amid US market volatility.

Conclusion

Orion Oyj's inclusion in the VanEck Global Healthcare Leaders ETF highlights its standing among international healthcare leaders. With a solid business in proprietary drugs and manufacturing, the company appeals to investors tracking global pharma trends. US portfolios gain diversified exposure through such funds, balancing regional risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.